Clinicopathological features of 20 cases of sporadic Burkitt lymphoma
| Case no./sex/age (years) | Stage | Extranodal lesion | Nodal lesion | Ki-67* | MUM1 | EBER | Treatment | Response | Follow-up |
| 1/M/2 | III | Abdominal cavity, mediastinum | Inguinal LN, retroperitoneal LN | 99.4±0.5 | NA | NA | CODOX-M/IVAC | CR | FOD, 15 months |
| 2/M/23 | IV | No | Cervical LN | 97.6±1.1 | NA | NA | Hyper-CVAD | CR | FOD, 17 months |
| 3/M/28 | II | No | Cervical LN, submaxillary LN, axillary LN | 95.0±2.5 | − | − | R-EPOCH+MTX | CR | FOD, 13 months |
| 4/F/39 | II | Oropharynx | Submaxillary LN, cervical LN | 96.8±1.8 | − | − | R-CODOX-M | NA | FOD, 14 months |
| 5/M/7 | III | Cardiodiaphragmatic angle | Coeliac LN, retroperitoneal LN | 95.0±2.5 | − | − | Prednisone/CTX/VCR | NA | DOD |
| 6/M/14 | II | Small intestine | Mesenteric LN | 95.8±0.8 | + | − | CODOX-M/IVAC+surgery | CR | FOD, 14 months |
| 7/M/7 | IV | Nasopharynx, liver | Cervical LN | 98.4±0.9 | + | − | BFM90 | CR | FOD, 16 months |
| 8/M/34 | IV | Nasal cavity, small intestine | External iliac LN | 95.8±1.1 | + | − | R-CODOX-M/R-IVAC | CR | FOD, 17 months |
| 9/M/4 | NA | No | Cervical LN | 94.4±0.9 | − | − | NA | NA | NA |
| 10/M/2 | III | Abdominal cavity, liver, spleen | Inguinal LN, mesenteric LN, pericardial LN, para-aortic LN | 98.6±2.1 | − | + | BFM90 | CR | FOD, 25 months |
| 11/F/67 | II | Pelvic cavity, retroperitoneum, thigh | Inguinal LN | 94.8±1.9 | NA | NA | CHOP | MODS | DOD, 2 months |
| 12/M/4 | II | Nasopharynx | Cervical LN | 99.6±0.9 | − | − | NA | NA | NA |
| 13/M/12 | III | Small intestine | Mesenteric LN | 94.8±1.9 | − | − | CTX/VCR | NA | NA |
| 14/M/40 | NA | Stomach | NA | 97.8±1.3 | − | + | NA | NA | NA |
| 15/M/4 | NA | Retroperitoneum | NA | 92.6±1.7 | − | + | NA | NA | NA |
| 16/M/34 | IV | Stomach, lung | Gastric LN | 91.6±2.5 | − | + | CODOX-M/IVAC+surgery | CR | FOD, 51 months |
| 17/M/30 | NA | Pelvic cavity, lung | No | 90.8±5.4 | − | − | NA | NA | FOD, 68 months |
| 18/M/10 | NA | Abdominal cavity | NA | 92.8±2.2 | − | + | NA | NA | NA |
| 19/M/5 | IV | Bilateral kidney | Cervical LN | 92.8±2.2 | − | − | BFM90 | CR | NA |
| 20/M/12 | NA | Sacrolumbus | No | 90.8±5.4 | − | − | NA | NA | NA |
↵* Mean (±SD) number of Ki-67-positive cells per 100 cells.
BFM, German Berlin-Frankfurt-Munster protocols; CHOP, cyclophosphamide, adriamycin, vincristine, prednisolone; CODOX-M, cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate; CTX, cyclophosphamide; DOD, dead of disease; EPOCH, etoposide, doxorubicin, cincristine, prednisone, cycolophosphamide; F, female; FOD, free of disease; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine; IVAC, ifosfamide, etoposide, high-dose cytarabine, along with intrathecal methotrexate and cytarabine; LN, lymph node; M, male; MTX, methotrexate; R, rituximab; VCR, vincristine; NA, not applicable; MODS: multiple system organ dysfunction syndrome; CR, complete response.